1.At a Glance
Once upon a caffeine molecule, deep in the pink city of Jaipur, a 1990-born extractor of green coffee beans decided to go public — and boom — the market couldn’t get enough of its “natural highs.” Shri Ahimsa Naturals Ltd, listed on NSE-SME in April 2025, has gone from a sleepy herbal extractor to a ₹607 crore caffeine empire with zero debt, a 24.4% ROCE, and enough export energy to keep Starbucks jittering.
At ₹260 per share, it’s up over60% in six months— and yet trades at a modestP/E of 22.4x, compared to industry averages above 35x. In Q2 FY26 (half-year ended Sept 2025), the company posted sales of₹60.5 crore, up 49% YoY, andPAT of ₹14.8 crore, up 53% YoY. That’s not caffeine — that’s compounding on steroids.
But before we crown them the “espresso kings of India,” let’s peek into the beans — the caffeine, the extracts, and the balance sheets. Because while Ahimsa preaches non-violence, its growth curve is brutally good.
2.Introduction
When you hear “Jaipur,” you think forts, marbles, and sweets — not a caffeine powerhouse exporting to nutraceutical giants across the globe. Yet Shri Ahimsa Naturals Ltd (SANL) has quietly built one of India’s most fascinating niche businesses: natural caffeine and botanical extracts.
Fromtea waste to treasury gain, SANL has extracted a golden goose out of green coffee beans and tea dust. The company’s flagship product,Caffeine Anhydrous Natural, forms 70% of its revenue — and no, that’s not your average coffee shop caffeine. This is pharma-grade, nutraceutical-grade, food-grade caffeine — the kind of stuff that powers your energy drinks, weight-loss pills, and those all-nighter “brain booster” supplements.
The company’s product portfolio screams diversification — not in theory, but in tonnage.270 MTPA caffeine,200 MTPA green coffee bean extract, and soon a700 MTPA expansionwith a brand-new facility via its subsidiary,Shri Ahimsa Healthcare Pvt Ltd.
But the real plot twist? It’s100% B2B. They don’t sell to you — they sell to the people who sell to you. Their top 10 customers account for 93.5% of sales, which sounds risky… unless you realize those customers are likely global nutraceutical giants who buy in bulk.
This is one of those rare SME stories where the business model is scientific, the financials are clean, and the management isn’t pledging shares to buy yachts.
3.Business Model – WTF Do They Even Do?
Let’s decode this caffeine cartel:
Shri Ahimsa Naturals extracts, refines, and exportsCaffeine Anhydrous NaturalandGreen Coffee Bean Extract (GCE)— both goldmines in the global nutraceutical and pharmaceutical markets. Add to that a supporting cast ofCrude Caffeineand a bunch ofherbal extractslike Ashwagandha, Turmeric (Curcumin), Bacopa Monnieri, and Garcinia Cambogia — basically, the Avengers of Ayurveda.
Here’s the trick:
- Theyextract crude caffeinefromtea and coffee waste(yes, literal waste).
- Then theypurify it into high-grade caffeine anhydrousused in pharma, cosmetics, and energy beverages.
- TheirGCE (Green Coffee Extract)is rich in chlorogenic acid — that magical ingredient behind every “fat burner” capsule.
Everything is done at their ISO-certified plant inJaipur, Rajasthan, with a capacity of270 MTPA caffeineand200 MTPA GCE. The next phase will jack this up to700 MTPA caffeineand500 MTPA GCE— that’s nearly3x production expansion.
They sell to nutraceutical, cosmetic, and F&B industries — allB2B exports, with86.5% of salesfrom exports (direct, deemed, and third-party combined).
So yes, you might not know them, but your Red Bull, your “natural energy pill,” and your post-workout fat burner
probably do.
4.Financials Overview (Half-Yearly Figures in ₹ Crores)
| Metric | Sep 2025 (Latest Half-Year) | Sep 2024 (YoY) | Mar 2025 (Prev Half-Year) | YoY % | QoQ % |
|---|---|---|---|---|---|
| Revenue | 60.5 | 40.7 | 55.0 | 48.6% | 10.0% |
| EBITDA | 18.0 | 12.2 | 17.0 | 47.5% | 5.9% |
| PAT | 14.8 | 9.7 | 12.0 | 52.7% | 23.3% |
| EPS (₹) | 6.36 | 4.17 | 5.25 | 52.5% | 21.1% |
(Data from Half-Yearly Results – Standalone)
Annualised EPS = ₹6.36 × 2 = ₹12.72At CMP ₹260 →P/E = 20.4x (very reasonable)
Commentary:The caffeine business is buzzing. Sales up nearly 50%, profits up 53%, margins stable around 30%. While most SMEs rely on debt to grow, Shri Ahimsa does it caffeine-style — no sleep, no debt, no drama.
5.Valuation Discussion – Fair Value Range (Educational Purpose Only)
Let’s brew three valuation approaches like a triple-shot espresso:
1. P/E Based Approach
- Annualised EPS = ₹12.72
- Industry P/E ≈ 20.5
- Fair Value Range = ₹12.72 × (18–25) =₹229 – ₹318
2. EV/EBITDA Based
- EV = ₹572 Cr, EBITDA = ₹39 Cr (TTM)
- EV/EBITDA = 14.6xIf we assume sector median multiple of 16–18x, Fair EV = 16×39 to 18×39 = ₹624–₹702 CrLess debt (₹0) → Fair Equity Value ≈ ₹624–₹702 CrPer Share (23 Cr equity shares) =₹271 – ₹305
3. Simplified DCF
Assuming 20% CAGR in FCF for next 5 years, discount rate 12%, terminal growth 4%, intrinsic value ≈₹240 – ₹310
📉Educational Fair Value Range: ₹230 – ₹310 per share
Disclaimer:This range is for educational discussion only, not investment advice.
6.What’s Cooking – News, Triggers, Drama
Ahimsa has been buzzing louder than a coffee grinder lately.
- IPO Mania:Listed in April 2025, raised ₹73.9 crore. ₹50 crore of that is being invested inShri Ahimsa Healthcare Pvt Ltdfor the Sawarda, Jaipur expansion — a caffeine factory 2.0.
- Monitoring Agency Drama:In Nov 2025, monitoring report flagged a ₹2.5 crore deviation (7.14%) — not a scam, just a paperwork hiccup. ₹25 crore remains unutilised, ₹10 crore invested.
- Preferential Issue Alert:In Oct 2025, Board

